ISOLATED HUMAN G-PROTEIN COUPLED RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR PROTEINS, AND USES THEREOF

Details for Australian Patent Application No. 2002237973 (hide)

Owner PE CORPORATION (NY)

Inventors DI FRANCESCO, Valentina; BEASLEY, Ellen, M.; GONG, Fangcheng; KETCHUM, Karen, A.

Pub. Number AU-A-2002237973

PCT Pub. Number WO2002/066644

Priority 09/784,317 16.02.01 US

Filing date 31 January 2002

Wipo publication date 4 September 2002

International Classifications

C12N 015/12 Mutation or genetic engineering - Genes encoding animal proteins

C12N 005/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C07K 014/705 Peptides having more than 20 amino acids

C12Q 001/68 Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 033/53 Investigating or analysing materials by specific methods not covered by groups - Immunoassay

A61K 045/00 Medicinal preparations containing active ingredients not provided for in groups

Event Publications

27 February 2003 Application Open to Public Inspection

  Published as AU-A-2002237973

12 February 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002237974-RETROVIRAL VECTOR

2002237972-Use of CD23 antagonists for the treatment of neoplastic disorders